Analytic and Clinical Validation of a 7-plex MIF Assay for Predictive Response of Advanced NSCLC to Anti-PD-1 based Therapy
7 重 MIF 检测对晚期 NSCLC 对抗 PD-1 治疗的预测反应的分析和临床验证
基本信息
- 批准号:10705736
- 负责人:
- 金额:$ 19.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-16 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:Advanced DevelopmentAgeAlgorithmic AnalysisAlgorithmsAntibodiesAntigensApplications GrantsBiological AssayBiological MarkersBiological SciencesBiopsyCD8B1 geneCancer CenterCd68Cell surfaceCellsClinicalCollaborationsCytokeratinDiseaseEvaluationFOXP3 geneFormalinGenderGeographyGoalsImage AnalysisImmuneImmunofluorescence ImmunologicImmunohistochemistryImmunooncologyIndividualInstitutionLabelLinkMalignant - descriptorMalignant Epithelial CellMedical centerMembraneMerkel cell carcinomaModalityMorphologic artifactsNon-Small-Cell Lung CarcinomaOutcomePD-1 pathwayPD-1/PD-L1PD-L1 blockadeParaffin EmbeddingParticipantPathologistPatient-Focused OutcomesPatientsPigmentsPositioning AttributeReagentReceiver Operating CharacteristicsReproducibilityResearch PersonnelResistanceResolutionSensitivity and SpecificitySiteSlideSolid NeoplasmSpecific qualifier valueSpecimenStainsStandardizationSurgical PathologyTestingTherapeutic AgentsTissue EmbeddingTissuesTonsilTumor MarkersTumor stageUniversitiesUpdateValidationWorkage relatedanti-PD-1anti-PD-L1anti-PD1 therapybiomarker developmentbiomarker identificationcell typeclinic readyclinical careclinical implementationcohortcombinatorialcompanion diagnosticsdensitydesignimaging approachimaging platformimmunotherapy clinical trialsimprovedindexinglight microscopyliquid crystal polymermelanomamultiparametric imagingmultiplex assayneoplastic cellnext generationphenotypic datapredicting responsepredictive testprognosticprogrammed cell death ligand 1programmed cell death protein 1research clinical testingresponsespectrographtumortumor microenvironmentwhole slide imaging
项目摘要
PROJECT SUMMARY
PD-L1 membranous (cell surface) expression in pretreatment biopsies is the most
commonly used correlate of the likelihood of response to anti-PD-1 therapy. The general finding
of an association of PD-L1 expression with tumor response to anti-PD-1 therapy has been
substantiated across tens of thousands of patients with numerous tumor types treated with anti-
PD-(L)1. However, while PD-L1 expression enriches for response to anti-PD-(L)1, it is not
sufficient. Additionally, while pathologists demonstrate good reproducibility for scoring tumor cell
(TC) PD-L1 expression by chromogenic IHC and light microscopy, they have poor reproducibility
for scoring PD-L1 expression on immune cells (IC).
Other related features which have been shown to improve on the PD-L1 biomarker include
the proximity of PD-1 to PD-L1, the density of CD8+FoxP3+ cells, and CD68 and tumor marker
immunostains, the latter of which help identify co-expression of PD-L1 on ICs and TCs,
respectively. A quantitative multiplex immunofluorescence assay which captures all of these
features has been developed and includes PD-L1, PD-1, CD8, FoxP3, CD68, a tumor marker
(cytokeratin AE1/3 for non-small cell lung carcinoma, NSCLC), a pan-membrane marker and
DAPI. Through this assay, it is possible to enumerate key cellular subsets and their co-expression
profiles. It is also possible to include spatial parameters, including the distance between PD-1 and
PD-L1, which have not previously been included in predictive or prognostic surgical pathology
specimen-based assays. This mIF assay has increased sensitivity and specificity for response to
anti-PD1 therapy when compared to the assessment of PD-L1 expression alone in multiple tumor
types, including melanoma, NSCLC, and Merkel cell carcinoma, amongst others.
The purpose of this proposal is to perform inter-site validation of the mIF staining assay
and associated lock-down algorithm amongst four major academic sites (Johns Hopkins, MD
Anderson, Yale University, and Providence Portland Medical Center). Following analytical
validation, discovery and validation cohorts from 250 patients with advanced NSCLC will be used
to establish final assay parameters (including thresholds), linked to clinical outcomes following
anti-PD-1-based therapy. The deliverable of the study is a refined, multiplex biomarker assay for
response/resistance to anti-PD-1 that has been validated across multiple academic sites. The
result will be a multiplex IF assay that is suitably staged for advanced development aimed at
clinical implementation. While NSCLC is the focus of the current grant proposal, preliminary
results suggest that this assay will also have great value in numerous other solid tumor types.
项目总结
PD-L1膜(细胞表面)在预处理活检组织中表达最多
常用的方法与抗PD-1治疗反应的可能性相关。总的发现是
PD-L1的表达与抗PD-1治疗的肿瘤反应之间的关系已被研究
在数以万计的多种肿瘤类型的患者中得到证实,这些患者接受了抗-
PD-(L)1。然而,尽管PD-L1的表达因对抗PD-(L)1的应答而丰富,但它不是
足够了。此外,虽然病理学家展示了对肿瘤细胞进行评分的良好重复性
(TC)PD-L1的显色免疫组化和光学显微镜表达,其重复性较差
用于免疫细胞(IC)上PD-L1表达的评分。
其他已被证明改善PD-L1生物标志物的相关特征包括
PD-1与PD-L1的亲和力、CD8+FoxP3+细胞密度、CD68和肿瘤标志物
免疫染色,后者有助于识别PD-L1在ICs和TCS上的共表达,
分别进行了分析。一种捕捉所有这些的定量多重免疫荧光分析
已开发的功能包括PD-L1、PD-1、CD8、FoxP3、CD68,一种肿瘤标记物
(非小细胞肺癌的细胞角蛋白AE1/3)、泛膜标记物和
DAPI。通过这种分析,有可能列举关键的细胞亚群及其共表达
配置文件。还可以包括空间参数,包括PD-1和PD-1之间的距离
PD-L1,以前没有包括在预测性或预后的外科病理学中
以样本为基础的分析。该MIF检测方法具有更高的敏感性和特异性
多发性肿瘤中抗PD1治疗与单独检测PD-L1表达的比较
类型,包括黑色素瘤、非小细胞肺癌和默克尔细胞癌等。
这项建议的目的是进行MIF染色分析的站点间验证
和四个主要学术站点(约翰·霍普金斯,马里兰州)之间的关联锁定算法
安德森、耶鲁大学和普罗维登斯波特兰医疗中心)。以下是分析
将使用来自250名晚期非小细胞肺癌患者的验证、发现和验证队列
确定最终化验参数(包括阈值),与以下临床结果相关联
抗PD-1为主的治疗。这项研究的成果是一种精炼的、多元化的生物标志物检测方法
对抗PD-1抗体的反应/抵抗力已在多个学术站点得到验证。这个
结果将是一种多重IF检测,适合于针对以下目标的高级开发
临床实施。虽然NSCLC是当前赠款提案的重点,但初步
结果表明,该检测方法在许多其他实体瘤类型中也有很大的应用价值。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Comparing and Correcting Spectral Sensitivities between Multispectral Microscopes: A Prerequisite to Clinical Implementation.
- DOI:10.3390/cancers15123109
- 发表时间:2023-06-08
- 期刊:
- 影响因子:5.2
- 作者:Eminizer, Margaret;Nagy, Melinda;Engle, Elizabeth L.;Soto-Diaz, Sigfredo;Jorquera, Andrew;Roskes, Jeffrey S.;Green, Benjamin F.;Wilton, Richard;Taube, Janis M.;Szalay, Alexander S.
- 通讯作者:Szalay, Alexander S.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Janis M Taube其他文献
USCAP 2018 Abstracts: Breast Pathology (121–337)
- DOI:
10.1038/modpathol.2018.3 - 发表时间:
2018-03-01 - 期刊:
- 影响因子:
- 作者:
Tricia R Cottrell;Anh T Duong;Christopher D Gocke;Haiying Xu;Aleksandra Ogurtsova;Janis M Taube;Deborah A Belchis - 通讯作者:
Deborah A Belchis
USCAP 2018 Abstracts: Hematopathology (1387–1604)
- DOI:
10.1038/modpathol.2018.13 - 发表时间:
2018-03-01 - 期刊:
- 影响因子:
- 作者:
Tricia R Cottrell;Anh T Duong;Christopher D Gocke;Haiying Xu;Aleksandra Ogurtsova;Janis M Taube;Deborah A Belchis - 通讯作者:
Deborah A Belchis
USCAP 2018 Abstracts: Infectious Disease Pathology (1605–1626)
- DOI:
10.1038/modpathol.2018.14 - 发表时间:
2018-03-01 - 期刊:
- 影响因子:
- 作者:
Tricia R Cottrell;Anh T Duong;Christopher D Gocke;Haiying Xu;Aleksandra Ogurtsova;Janis M Taube;Deborah A Belchis - 通讯作者:
Deborah A Belchis
USCAP 2018 Abstracts: Index of Abstract Authors
- DOI:
10.1038/modpathol.2018.25 - 发表时间:
2018-03-01 - 期刊:
- 影响因子:
- 作者:
Tricia R Cottrell;Anh T Duong;Christopher D Gocke;Haiying Xu;Aleksandra Ogurtsova;Janis M Taube;Deborah A Belchis - 通讯作者:
Deborah A Belchis
USCAP 2018 Abstracts: Endocrine Pathology (615–656)
- DOI:
10.1038/modpathol.2018.8 - 发表时间:
2018-03-01 - 期刊:
- 影响因子:
- 作者:
Tricia R Cottrell;Anh T Duong;Christopher D Gocke;Haiying Xu;Aleksandra Ogurtsova;Janis M Taube;Deborah A Belchis - 通讯作者:
Deborah A Belchis
Janis M Taube的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Janis M Taube', 18)}}的其他基金
Analytic and Clinical Validation of a 7-plex MIF Assay for Predictive Response of Advanced NSCLC to Anti-PD-1 based Therapy
7 重 MIF 检测对晚期 NSCLC 对抗 PD-1 治疗的预测反应的分析和临床验证
- 批准号:
10506186 - 财政年份:2022
- 资助金额:
$ 19.19万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 19.19万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 19.19万 - 项目类别:
Continuing Grant
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 19.19万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 19.19万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 19.19万 - 项目类别:
Fellowship
Walkability and health-related quality of life in Age-Friendly Cities (AFCs) across Japan and the Asia-Pacific
日本和亚太地区老年友好城市 (AFC) 的步行适宜性和与健康相关的生活质量
- 批准号:
24K13490 - 财政年份:2024
- 资助金额:
$ 19.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Discovering the (R)Evolution of EurAsian Steppe Metallurgy: Social and environmental impact of the Bronze Age steppes metal-driven economy
发现欧亚草原冶金的(R)演变:青铜时代草原金属驱动型经济的社会和环境影响
- 批准号:
EP/Z00022X/1 - 财政年份:2024
- 资助金额:
$ 19.19万 - 项目类别:
Research Grant
ICF: Neutrophils and cellular senescence: A vicious circle promoting age-related disease.
ICF:中性粒细胞和细胞衰老:促进与年龄相关疾病的恶性循环。
- 批准号:
MR/Y003365/1 - 财政年份:2024
- 资助金额:
$ 19.19万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 19.19万 - 项目类别:
Standard Grant
Shaping Competition in the Digital Age (SCiDA) - Principles, tools and institutions of digital regulation in the UK, Germany and the EU
塑造数字时代的竞争 (SCiDA) - 英国、德国和欧盟的数字监管原则、工具和机构
- 批准号:
AH/Y007549/1 - 财政年份:2024
- 资助金额:
$ 19.19万 - 项目类别:
Research Grant